---
document_datetime: 2025-12-02 05:07:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sugammadex-fresenius-kabi.html
document_name: sugammadex-fresenius-kabi.html
version: success
processing_time: 0.1073961
conversion_datetime: 2025-12-28 14:47:02.627788
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sugammadex Fresenius Kabi

[RSS](/en/individual-human-medicine.xml/67583)

##### Authorised

This medicine is authorised for use in the European Union

sugammadex Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sugammadex Fresenius Kabi](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sugammadex Fresenius Kabi is a medicine used to reverse the effect of the muscle relaxants rocuronium and vecuronium. Muscle relaxants are medicines used during some types of operation to make the muscles relax, including the muscles that help the patient to breathe. Muscle relaxants make it easier for the surgeon to do the operation. Sugammadex Fresenius Kabi is used to speed up the recovery from the muscle relaxant, usually at the end of the operation.

Sugammadex Fresenius Kabi can be used in adults who have received rocuronium and vecuronium, and in children aged 2 years or older who have received rocuronium.

Sugammadex Fresenius Kabi contains the active substance sugammadex and is a 'generic medicine'. This means that Sugammadex Fresenius Kabi contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Bridion. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Sugammadex Fresenius Kabi used?

Sugammadex Fresenius Kabi can only be obtained with a prescription. It is given by or under the supervision of an anaesthetist (a doctor specialised in anaesthesia). Sugammadex Fresenius Kabi is given into a vein as a single 'bolus' injection (given all at once). The dose depends on the patient's body weight and on how much the muscle relaxant is affecting the muscles.

For more information about using Sugammadex Fresenius Kabi, see the package leaflet or contact your doctor or pharmacist.

## How does Sugammadex Fresenius Kabi work?

The active substance in Sugammadex Fresenius Kabi, sugammadex, is a 'selective relaxant binding agent'. This means that it attaches to the muscle relaxants rocuronium and vecuronium forming a 'complex' that inactivates the muscle relaxants and stops them having an effect. As a result, the muscles contract and begin to work normally again, including the muscles that help the patient to breathe.

## How has Sugammadex Fresenius Kabi been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Bridion, and do not need to be repeated for Sugammadex Fresenius Kabi.

As for every medicine, the company provided data on the quality of Sugammadex Fresenius Kabi. There was no need for 'bioequivalence' studies to investigate whether Sugammadex Fresenius Kabi is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Sugammadex Fresenius Kabi is given by injection into a vein, so the active substance is delivered straight into the bloodstream.

## What are the benefits and risks of Sugammadex Fresenius Kabi?

Because Sugammadex Fresenius Kabi is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Sugammadex Fresenius Kabi authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Sugammadex Fresenius Kabi has been shown to be comparable to Bridion. Therefore, the Agency's view was that, as for Bridion, the benefits of Sugammadex Fresenius Kabi outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Sugammadex Fresenius Kabi?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sugammadex Fresenius Kabi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sugammadex Fresenius Kabi are continuously monitored. Suspected side effects reported with Sugammadex Fresenius Kabi are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sugammadex Fresenius Kabi

Sugammadex Fresenius Kabi received a marketing authorisation valid throughout the EU on 15 July 2022.

Sugammadex Fresenius Kabi : EPAR - Medicine overview

Reference Number: EMEA/H/C/005760

English (EN) (144.33 KB - PDF)

**First published:** 21/07/2022

[View](/en/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-246)

български (BG) (157.88 KB - PDF)

**First published:**

21/07/2022

[View](/bg/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_bg.pdf)

español (ES) (135.99 KB - PDF)

**First published:**

21/07/2022

[View](/es/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_es.pdf)

čeština (CS) (155.86 KB - PDF)

**First published:**

21/07/2022

[View](/cs/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_cs.pdf)

dansk (DA) (134.99 KB - PDF)

**First published:**

21/07/2022

[View](/da/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_da.pdf)

Deutsch (DE) (138.29 KB - PDF)

**First published:**

21/07/2022

[View](/de/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_de.pdf)

eesti keel (ET) (123.48 KB - PDF)

**First published:**

21/07/2022

[View](/et/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (159.85 KB - PDF)

**First published:**

21/07/2022

[View](/el/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_el.pdf)

français (FR) (136.68 KB - PDF)

**First published:**

21/07/2022

[View](/fr/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (153.52 KB - PDF)

**First published:**

21/07/2022

[View](/hr/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_hr.pdf)

italiano (IT) (134.89 KB - PDF)

**First published:**

21/07/2022

[View](/it/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (165.45 KB - PDF)

**First published:**

21/07/2022

[View](/lv/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (155.18 KB - PDF)

**First published:**

21/07/2022

[View](/lt/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_lt.pdf)

magyar (HU) (155.57 KB - PDF)

**First published:**

21/07/2022

[View](/hu/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_hu.pdf)

Malti (MT) (157.23 KB - PDF)

**First published:**

21/07/2022

[View](/mt/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (134.75 KB - PDF)

**First published:**

21/07/2022

[View](/nl/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_nl.pdf)

polski (PL) (158.98 KB - PDF)

**First published:**

21/07/2022

[View](/pl/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_pl.pdf)

português (PT) (135.76 KB - PDF)

**First published:**

21/07/2022

[View](/pt/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_pt.pdf)

română (RO) (154.01 KB - PDF)

**First published:**

21/07/2022

[View](/ro/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (156.32 KB - PDF)

**First published:**

21/07/2022

[View](/sk/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (153.12 KB - PDF)

**First published:**

21/07/2022

[View](/sl/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_sl.pdf)

Suomi (FI) (134.03 KB - PDF)

**First published:**

21/07/2022

[View](/fi/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_fi.pdf)

svenska (SV) (133.94 KB - PDF)

**First published:**

21/07/2022

[View](/sv/documents/overview/sugammadex-fresenius-kabi-epar-medicine-overview_sv.pdf)

Sugammadex Fresenius Kabi : EPAR - Risk management plan

English (EN) (247.5 KB - PDF)

**First published:** 21/07/2022

**Last updated:** 11/07/2025

[View](/en/documents/rmp/sugammadex-fresenius-kabi-epar-risk-management-plan_en.pdf)

## Product information

Sugammadex Fresenius Kabi : EPAR - Product Information

English (EN) (432.75 KB - PDF)

**First published:** 21/07/2022

**Last updated:** 11/07/2025

[View](/en/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-86)

български (BG) (523.04 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/bg/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_bg.pdf)

español (ES) (455.69 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/es/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_es.pdf)

čeština (CS) (496.36 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/cs/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_cs.pdf)

dansk (DA) (517.14 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/da/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_da.pdf)

Deutsch (DE) (463.38 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/de/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_de.pdf)

eesti keel (ET) (456.46 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/et/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_et.pdf)

ελληνικά (EL) (585.21 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/el/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_el.pdf)

français (FR) (525.83 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/fr/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_fr.pdf)

hrvatski (HR) (508 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/hr/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_hr.pdf)

íslenska (IS) (491.23 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/is/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_is.pdf)

italiano (IT) (436.09 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/it/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_it.pdf)

latviešu valoda (LV) (511.27 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/lv/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (470.68 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/lt/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_lt.pdf)

magyar (HU) (541.07 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/hu/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_hu.pdf)

Malti (MT) (641.18 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/mt/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_mt.pdf)

Nederlands (NL) (495.88 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/nl/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_nl.pdf)

norsk (NO) (442.24 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/no/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_no.pdf)

polski (PL) (457.34 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/pl/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_pl.pdf)

português (PT) (273.59 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/pt/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_pt.pdf)

română (RO) (513.85 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/ro/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_ro.pdf)

slovenčina (SK) (485.57 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/sk/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_sk.pdf)

slovenščina (SL) (503.33 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/sl/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_sl.pdf)

Suomi (FI) (406.68 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/fi/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_fi.pdf)

svenska (SV) (455.01 KB - PDF)

**First published:**

21/07/2022

**Last updated:**

11/07/2025

[View](/sv/documents/product-information/sugammadex-fresenius-kabi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000265804 09/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sugammadex Fresenius Kabi : EPAR - All Authorised Presentations

English (EN) (42.48 KB - PDF)

**First published:** 21/07/2022

[View](/en/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-636)

български (BG) (49.59 KB - PDF)

**First published:**

21/07/2022

[View](/bg/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_bg.pdf)

español (ES) (41.22 KB - PDF)

**First published:**

21/07/2022

[View](/es/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (49.27 KB - PDF)

**First published:**

21/07/2022

[View](/cs/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (43.59 KB - PDF)

**First published:**

21/07/2022

[View](/da/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (48.32 KB - PDF)

**First published:**

21/07/2022

[View](/de/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (39.88 KB - PDF)

**First published:**

21/07/2022

[View](/et/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (46.34 KB - PDF)

**First published:**

21/07/2022

[View](/el/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_el.pdf)

français (FR) (45.2 KB - PDF)

**First published:**

21/07/2022

[View](/fr/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (42.7 KB - PDF)

**First published:**

21/07/2022

[View](/hr/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (44.91 KB - PDF)

**First published:**

21/07/2022

[View](/is/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (41.15 KB - PDF)

**First published:**

21/07/2022

[View](/it/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (46.02 KB - PDF)

**First published:**

21/07/2022

[View](/lv/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (45.84 KB - PDF)

**First published:**

21/07/2022

[View](/lt/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (46.14 KB - PDF)

**First published:**

21/07/2022

[View](/hu/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (43.77 KB - PDF)

**First published:**

21/07/2022

[View](/mt/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (41.6 KB - PDF)

**First published:**

21/07/2022

[View](/nl/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (50.44 KB - PDF)

**First published:**

21/07/2022

[View](/no/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_no.pdf)

polski (PL) (49.15 KB - PDF)

**First published:**

21/07/2022

[View](/pl/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_pl.pdf)

português (PT) (42.97 KB - PDF)

**First published:**

21/07/2022

[View](/pt/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_pt.pdf)

română (RO) (47.01 KB - PDF)

**First published:**

21/07/2022

[View](/ro/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (48.69 KB - PDF)

**First published:**

21/07/2022

[View](/sk/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (45.38 KB - PDF)

**First published:**

21/07/2022

[View](/sl/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (39.22 KB - PDF)

**First published:**

21/07/2022

[View](/fi/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.34 KB - PDF)

**First published:**

21/07/2022

[View](/sv/documents/all-authorised-presentations/sugammadex-fresenius-kabi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sugammadex Fresenius Kabi Active substance sugammadex sodium International non-proprietary name (INN) or common name sugammadex Therapeutic area (MeSH) Neuromuscular Blockade Anatomical therapeutic chemical (ATC) code V03AB35

### Pharmacotherapeutic group

All other therapeutic products

### Therapeutic indication

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

## Authorisation details

EMA product number EMEA/H/C/005760

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Fresenius Kabi Deutschland GmbH

Else-Kröner-Straße 1,

Opinion adopted 19/05/2022 Marketing authorisation issued 15/07/2022 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sugammadex Fresenius Kabi : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (160.11 KB - PDF)

**First published:** 25/03/2025

**Last updated:** 11/07/2025

[View](/en/documents/procedural-steps-after/sugammadex-fresenius-kabi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Sugammadex Fresenius Kabi : EPAR - Public Assessment Report

Reference Number: EMA/612933/2022

English (EN) (370.74 KB - PDF)

**First published:** 21/07/2022

[View](/en/documents/assessment-report/sugammadex-fresenius-kabi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sugammadex Fresenius Kabi

Adopted

Reference Number: EMA/CHMP/266795/2022

English (EN) (150.72 KB - PDF)

**First published:** 20/05/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sugammadex-fresenius-kabi_en.pdf)

#### News on Sugammadex Fresenius Kabi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022) 20/05/2022

**This page was last updated on** 11/07/2025

## Share this page

[Back to top](#main-content)